United States: Biobetters: The Advantages And Challenges Of Being Better

Last Updated: July 1 2015
Article by Irena Royzman and Andrew D. Cohen

The Biologics Price Competition and Innovation Act of 2009 (BPCIA) was passed as part of health reform signed into law by President Barack Obama in March 2010. The BPCIA created an abbreviated pathway for Food and Drug Administration approval of biologic medicinal products that are ''biosimilar'' to an already FDA-approved product. Because biologic drugs, also referred to as biologics, are complex molecules made in living organisms rather than chemically synthesized, biosimilars are not copies of an approved biologic product. Instead, the BPCIA requires a biosimilar to be ''highly similar'' to the approved product without any clinically meaningful differences in terms of safety, purity and potency.

The FDA recently approved the first U.S. biosimilar: Sandoz's biosimilar of Amgen's Neupogen, a blockbuster drug used to prevent infections in cancer patients. While the FDA currently is reviewing four other proposed biosimilars and additional applications for approval of biosimilar versions of some of the most successful biologic medicines are expected shortly, many innovators and biosimilar manufacturers are responding to the changing landscape for biologics by developing ''biobetters'': new and improved versions of biologic medicinal products.

While biobetters require discovery and an original Biologics License Application (BLA) with a full complement of pre-clinical and clinical data for marketing approval, they also offer many advantages. By offering a superior or longer-acting medicine, biobetters provide a competitive advantage over biosimilar products. In addition, unlike biosimilars, they generally would be entitled to patent protection and 12 years of non-patent exclusivity under the BPCIA.


Biobetters can provide a substantial difference in clinical efficacy, safety or convenience and they may have fewer side effects or less frequent dosing. Amgen's Neulasta, an improved long-acting version of Amgen's Neupogen that was approved by the FDA in 2002, is one of the early examples of biobetters. Neulasta consists of Neupogen with a covalently bound polyethylene glycol (PEG) molecule that allows Neulasta to be administered less frequently. While Neupogen is administered once daily during a chemotherapy cycle, Neulasta is administered only once per chemotherapy cycle. U.S. sales in fiscal year 2014 for Neulasta were approximately $3.8 billion as opposed to only $880 million for Neupogen, reflecting the commercial value of a biobetter.

Biobetter Strategies

Manufacturers are employing a number of strategies to create biosimilars and many more biobetters are being developed in the face of impending biosimilar competition.

Pegylation (i.e., the addition of PEG) is being used to create long-acting versions of successful biologics. In addition to Amgen's Neulasta, a number of companies have used pegylation to make biobetters of their own drugs or those of other innovators. For example, Roche created a pegylated biobetter of Amgen's Epogen that is sold as Mircera. In 2007, the FDA approved Mircera for once-monthly dosing to anemic patients as opposed to weekly dosing for Epogen. Last year, Biogen Idec obtained approval for Plegridy, a pegylated long-acting version of its own Avonex, a treatment for multiple sclerosis.

Innovators also are actively pursuing a number of strategies to create biobetters of some of the most successful antibody products. One such strategy is to prepare a fragment of the originator antibody that retains the efficacy of the antibody, but confers benefits in terms of delivery or safety. For example, Roche's Lucentis, approved to treat age-related macular degeneration and edema, is a fragment of Roche's Avastin antibody, a treatment for colon and other cancers. The antibody fragment may penetrate the eye's retina better than the full antibody and only Lucentis is approved for ophthalmic use.

Antibody-drug conjugates represent another approach to developing biobetters. Roche's Kadcyla, approved in 2013, is a recent example of that strategy. Kadcyla is a conjugate of a cancer-killing agent with Roche's Herceptin antibody, a blockbuster breast cancer treatment. The antibody inhibits a protein that is over-expressed in certain breast cancers. Kadcyla also delivers the cancer-killing agent site-selectively, a one-two punch.

Attempts to reduce a patient's unwanted immune reaction to chimeric antibodies, antibodies with mouse and human protein sequences, have led to the development of humanized biobetters, i.e., antibodies where many of the mouse sequences are replaced with human ones. Roche, as an example, is developing ocrelizumab, a humanized analog of the chimeric Rituxan antibody for treatment of multiple sclerosis. This humanized version of Rituxan is now in phase III clinical trials.

In 2013, Roche obtained approval of another humanized antibody, Gazyva, a Rituxan biobetter that is also known as ''Son of Rituxan.'' Gazyva, a therapy for chronic lymphocytic leukemia, is also engineered to more efficiently trigger an immune response and clear cancer cells. The FDA gave Gazyva a breakthrough therapy designation based on clinical evidence indicating that it offers a ''substantial improvement'' over available therapies, such as Rituxan. If approved for other Rituxan indications, Gazyva is poised to take over the Rituxan market, potentially before biosimilar competition.

Advantages of Biobetters

Biobetters have the potential to offer tremendous commercial advantages over originator or biosimilar drugs as well as to receive patent protection and market exclusivity.

Commercial Value

By providing a more effective or longer-acting medicine, biobetters create the potential to take over and control the market prior to entry of biosimilars of the originator drug. For example, in Europe, where biosimilars of Neupogen are marketed at a 20 percent to 30 percent discount over Neupogen, Amgen has retained significant market share by having Neulasta to offer patients.1 Neulasta, as a long-acting biobetter of Neupogen, provides advantages to patients that Neupogen or its biosimilars do not have. Similarly, although Granix, Teva's version of Amgen's Neupogen, has been on the U.S. market since 2013, Neulasta continues to be a blockbuster product in the U.S. due to the benefits it provides to patients.

Biobetters also have the potential to reduce healthcare costs due to greater therapeutic efficacy or by having to be administered less frequently, as in the case of Neulasta. Also, unlike biosimilars, biobetters are not faced with the burden of having to be similar to the originator biologic. This frees companies to use more modern and potentially less costly manufacturing methods. In addition, as a better or more convenient medicine, biobetters offer a marketing advantage over the originator biologic or its biosimilars.


Biobetters also are likely eligible for patent protection. Patents can potentially be obtained for the biobetter itself, a pharmaceutical composition of the biobetter, a method of treatment or manufacture. Biobetters may be eligible for all of the same types of patent protection available for originator biologics. Amgen, for example, obtained patent protection for its Neulasta biobetter. Similarly, Roche obtained patent protection for Mircera (a biobetter of Amgen's Epogen), Gazyva (a biobetter of Roche and Biogen's Rituxan antibody) and Kadcyla (a biobetter of Roche's Herceptin antibody).

Regulatory Advantages and Non-Patent Exclusivity

Biobetters, just as any new biologics, allow manufacturers to avoid the complex litigation provisions, a 12- year bar to final FDA approval and regulatory uncertainty associated with the BPCIA. Because biobetters are approved through submission of a full BLA rather than an abbreviated BLA (aBLA), they are not subject to the litigation provisions of the BPCIA and are not blocked by the originator biologic's 12 years of non-patent exclusivity provided in the BPCIA. Under the BPCIA, a biosimilar cannot receive final regulatory approval from the FDA and cannot be marketed until the reference biologic has enjoyed 12 years of marketing exclusivity from the time it was first licensed. By contrast, the FDA can approve biobetters at any point in time, and therefore biobetters can enter the market prior to the marketing of any biosimilars.

Further, while approval of a biologic through a traditional BLA with a full complement of pre-clinical and clinical data is much more costly than approval through submission of an aBLA, the BPCIA is still a largely untested regulatory pathway. To date, only Sandoz's biosimilar of Neupogen, known as Zarxio, has been approved through the BPCIA regulatory pathway. While Zarxio's approval earlier this year was a milestone event, it is unlikely to offer significant insight into the regulatory requirements for obtaining approval of complex biologics due to its simplicity. Zarxio is a small protein made in bacteria with no glycosylation (attached sugars). Biobetters, by being approved through submission of a traditional BLA, benefit from a more certain and established regulatory approval pathway.

As with other new biologics, the BPCIA provides a significant advantage to biobetters. Biobetters have the potential to receive their own 12 years of market exclusivity from biosimilar competition. The BPCIA automatically provides biobetters with that advantage if the regulatory application is filed by a company that is not related to or a licensee of the company that applied for or manufactured the originator biologic. When the company that applied for approval of the originator biologic seeks FDA approval of a biobetter of its own product, the biobetter will likely receive 12 years of market exclusivity as long as it is a true biobetter, i.e., it is (1) structurally different from the originator biologic and (2) provides a change in safety, purity or potency as compared to the originator product.2

Guidance from the FDA confirms that biobetters likely will be entitled to their own 12-year exclusivity.3 The FDA considers any of the following differences to be a structural modification of the originator biologic for purposes of the 12-year exclusivity provision of the BPCIA: ''any differences in amino acid sequence, glycosylation patterns, tertiary structures, post-translational events (including any chemical modifications of the molecular structure such as pegylation), and infidelity of translation or transcription, among others.'' The typical biobetters strategies, discussed above, all meet this requirement.

In assessing whether such structural differences result in a change in safety, purity or potency as compared to the originator product, the FDA intends to make a case-by-case determination based on information provided by the biobetter applicant about a ''measurable effect (typically demonstrated in preclinical or clinical studies and shown by relevant methods such as bioassays).'' The FDA recommends that the biobetter applicant present ''evidence that the change will result in a meaningful benefit to public health, such as a therapeutic advantage or other substantial benefit when compared to the previously licensed biological product.'' Since the goal of biobetter development is to provide a superior medicine that is meaningfully different in terms of safety, purity or potency, this further requirement should be readily met, providing the biobetter with 12 years of non-patent exclusivity against biosimilar entrants.

Challenges of Biobetters

Biobetters also pose formidable challenges. As with originator biologics, biobetter development is fraught with risk and requires significant research and development. Biobetters are bound to have a higher success rate than originator biologics due to a validated target for the biologic, but an improved biologic is far from certain and may require significant experimentation. In addition, biobetters may have new and unexpected side effects that are different from that of the originator biologic. Approval of a biobetter also requires a traditional BLA with a full complement of pre-clinical and clinical data. As a result, research and development costs for biobetters will be significantly greater than that for a biosimilar of an originator biologic and approach that of an originator biologic. But the development of the biobetter benefits from the established efficacy of the originator biologic and validated target.


Biobetters are here now, but, as biosimilar competition looms, biobetters may become the better approach for all biologics manufacturers. With the promise of 12 years of market exclusivity, the possibility of patent protection and the hope of capturing a market before competition arrives, the most important consequence of the BPCIA may not be the introduction of biosimilars, but the incentive for biobetters.

Originally published by Bloomberg BNA's Life Sciences Law & Industry Report.


1. Henry Grabowski et al., Biosimilar competition: lessons from Europe, Nature Reviews: Drug Discovery, 13, 99-100 (Feb. 2014).

2. 42 U.S.C. §§ 262(k)(7)(A) & (C).

3. FDA, Draft Guidance for Industry: Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act (Aug. 2014), available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM407844.pdf.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement

    Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of www.mondaq.com

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at enquiries@mondaq.com.

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions